Introduction
Colorectal cancer (CRC) is the fourth most common cancer in the United States and the second leading cause of cancer-related deaths. In the past decade, targeted therapies have increased the median overall survival for metastatic CRC from 12 months to 30 months. 1 Recent data emerging from The Cancer Genome Atlas have identified subtypes of colon cancer associated with common oncogenic pathways. 2 One area of particular interest involves a subset of CRC with mismatch repair (MMR) deficiency associated with a hypermutated phenotype. This phenotype of CRC potentially results from thousands of mutations linked to inherited MMR mechanisms (eg, Lynch syndrome) or sporadic cancers associated with somatic mutations or epigenetic phenomenon, including gene promoter methylation, which leads to silencing of gene expression. Knowledge of the mutations responsible for CRC biology provides the opportunity for developing therapeutic targets. Instability of microsatellites, both truncated and expanded, are observed in 20% of early-stage CRC cases and 5% of advancedstage CRC cases. 3 High microsatellite instability (MSI) is often associated with a high mutation burden, in the range of thousands per megabase. MSI cancers increase recognition by the cytotoxic T lymphocytes and have a better prognosis compared with stable microsatellite tumors. 4, 5 Most CRC cases arising from MMR are secondary to somatic mutations, with a few arising from germline mutations such as Lynch syndrome. 6 The 4 genes associated with Lynch syndrome are MLH1, MSH2, MSH6, and PMS2. Sporadic deficiencies in MMR result from MLH1 methylation, which produces complete loss of the MMR pathway. 6 Immune surveillance plays a role in CRC regulation, and tumor dysregulation of immune checkpoints might contribute to immune resistance mechanisms. 7 Therapeutic manipulation to promote CRC antitumor immunity has been studied. Two immune checkpoint inhibitors, CTLA4 and PD-1 antibodies, increase the immune response in CRC tumors with high MSI. 8 Although most patients with advanced CRC will not benefit from single-agent immune checkpoint inhibitors, the results from phase II studies have suggested a disease control rate of 70% in patients treated with single-agent nivolumab or pembrolizumab. (5-FU) to enhance antitumor immunity by elimination of myeloid-derived tumor suppressive cells and increased interferon-g production by tumor-specific CD8 þ cells. Preclinical studies have established the role of chemotherapy drugs as immune modulating agents that could be synergistic with immune checkpoint inhibitors against CRC. In mouse models, oxaliplatin has been reported to induce immunogenic cell death, leading to release of neoantigens, which are engulfed by dendritic cells and presented to tumor-specific CD8 þ T cells.
11,12
Based on previously reported data, a clinical trial was designed to evaluate the safety and efficacy of mFOLFOX6 (5-FU, leucovorin, oxaliplatin) combined with pembrolizumab for patients with advanced, unresectable CRC, irrespective of their MMR status. In the present study, we report a complete pathologic response in a patient with dMMR CRC who had received mFOLFOX6 with pembrolizumab after only 2 months of therapy as observed at surgical resection.
Case Report
A 28-year-old woman presented with diarrhea and hematochezia of several months' duration. Colonoscopy demonstrated evidence of a large sigmoid colon mass. The biopsy results revealed a poorly differentiated adenocarcinoma of the colon. A 3-generation pedigree with emphasis on cancers and tumors was obtained during genetic counselling, which revealed her paternal grandfather had died of colorectal cancer at the age of 32. Immunohistochemical stains with working controls were performed on the specimen. The cancer cells were strongly and diffusely positive for keratin cocktail and CDX2, with negative staining for CK7, CK20, synaptophysin, chromogranin, and PAX-8. Immunohistochemical stains for the MMR proteins MLH1, MSH2, MSH6, and PMS2 were performed, with evidence of loss of expression of MLH1 and PMS2 and normal expression of MSH2 and MSH6. The patient received genetic counseling to discuss confirmation of Lynch syndrome, and her father was recommended to be tested for MLH1 mutation given the paternal history of early CRC.
Further molecular studies showed BRAF V600E wild-type and KRAS G12D mutations. Her tumor was evaluated using FoundationOne, and evidence of BRCA2, CDK12, PIK3CA, PTEN, APC, ARID1A, ARID2, CIC, CREBBP, FAT1, MLH1, MSH2, SPTA1, and TP53 mutations and a high tumor mutation burden of 48.71 muts/Mb were found. Despite the retained expression of MSH2 and loss of PMS2 on immunohistochemistry, the findings from the FoundationOne next-generation sequencing identified a mutation in MSH2. The patient underwent positron emission tomography, which demonstrating evidence of large central hepatic mass with extrahepatic extensive lymphadenopathy in the porta hepatis and para-aortic region (Figure 1) .
She was enrolled in a clinical trial (ClinicalTrial.gov identifier, NCT02375672) and was treated with mFOLFOX6 every 2 weeks and pembrolizumab 200 mg intravenously every 3 weeks. 
Discussion
Although MMR deficiency has long been associated with improved survival for patients with early-stage CRC, 4,5 the association with advanced disease suggested worse outcomes. However, this phenotype has typically been associated with increased tumor infiltrating lymphocytes, which has been associated with improved survival in a subset of patients with advanced CRC. MMR deficiency, irrespective of the tissue of origin. Because the use of pembrolizumab is limited to < 5% of all patients with advanced incurable CRC, efforts are underway to overcome the innate resistance to immunotherapy. One approach is to combining immunotherapy with chemotherapy, which can lead to immunogenic cell death, and other agents that can enhance tumor lymphocyte trafficking. 15, 16 Both chemotherapy and radiation provoke adaptive immune responses in CRC, promoting tumor cell death, and current research is examining the benefits of combining current treatments with immunotherapy. 5-FU and oxaliplatin are thought to aid immune cell-mediated death. Thus, 2 trials (ClinicalTrials.gov identifiers, NCT02375672 and NCT02268825) are studying the combination of FOLFOX and pembrolizumab in gastrointestinal and colon cancers. 17 The present patient and other patients are still being followed up in the NCT02375672 trial, and the preliminary results of the study have been reported at the American Society of Clinical Oncology 2017 annual meeting. 18 In a small study (ClinicalTrials.gov identifier, NCT01633970) of 14 patients with chemorefractory disease, a combination of atezolizumab (an antiePD-L1 monoclonal antibody) and bevacizumab (for VEGF blockade), without chemotherapy, demonstrated a disease response (7%) or stability (64%). 17 Additional CRC studies of chemoimmunotherapy combinations include a regimen of bevacizumab and FOLFOX, which led to increased inflammatory helper T cells. 19 Finally, a combined chemoimmunotherapy trial with FOLFOX, bevacizumab, and atezolizumab in treatment-naive patients has shown a disease response or stable disease in 87% of the patients. 20 Multiple other studies are underway to examine various chemoimmunotherapy combinations for advanced CRC cases. 21 Although responses to single-agent PD-1 inhibitors have been reported, and a complete pathologic response has been documented after an extended course of pembrolizumab, 13 our report describes a case of a dramatic response to a combination of chemotherapy and pembrolizumab with complete tumor necrosis and pathologic response within only 2 months of therapy. Although the presence of dMMR can explain the benefit from pembrolizumab, the number of molecular abnormalities could have contributed to the massive antigen presentation associated with chemotherapy. This is, in part, due to the activity associated with mFOLFOX6 in the first-line setting (response rate of w50%) and the presence of abnormalities in DNA homologous recombination repair genes (BRCA2, ARID1A, and ARID2), which might confer sensitivity to platinum-based therapy.
Conclusion
The present case raises a number of questions, including (1) the optimal imaging modality to assess for treatment response; (2) the role of chemotherapy to enhance responses to immune checkpoint inhibitors, especially to enhance activity in dMMR or to overcome innate resistance in proficient MMR; and (3) the ideal duration of therapy. Several studies have demonstrated prolonged and sustained responses in a subset of patients with melanoma and other solid tumors who discontinued therapy for variable reasons, including initial progression that was followed by a delayed response. Future studies are needed to answer these important questions, especially because of the costs associated with this novel class of drugs and the risk of immune-mediated toxicity.
